cinobufagin and Leukemia--Promyelocytic--Acute
cinobufagin has been researched along with Leukemia--Promyelocytic--Acute* in 1 studies
Other Studies
1 other study(ies) available for cinobufagin and Leukemia--Promyelocytic--Acute
Article | Year |
---|---|
Cinobufagin induces acute promyelocytic leukaemia cell apoptosis and PML-RARA degradation in a caspase-dependent manner by inhibiting the β-catenin signalling pathway.
Acute promyelocytic leukaemia (APL) is a malignant hematological tumour characterized by the presence of promyelocytic leukaemia-retinoic acid receptor A (PML-RARA) fusion protein. Cinobufagin (CBG) is one of the main effective components of toad venom with antitumor properties. However, only a few reports regarding the CBG treatment of APL are available.. We explored the effect and mechanism of action of CBG on NB4 and NB4-R1 cells.. We evaluated the viability of NB4 and NB4-R1 cells treated with 0, 20, 40, and 60 nM CBG for 12, 24, and 48 h. After treatment with CBG for 24 h, Bcl-2 associated X (Bax), B-cell lymphoma 2 (Bcl-2), β-catenin, cyclin D1, and c-myc expression was detected using western blotting and real-time polymerase chain reaction. Caspase-3 and PML-RARA expression levels were detected using western blotting.. CBG inhibited the viability of NB4 and NB4-R1 cells. The IC. CBG induced NB4 and NB4-R1 cell apoptosis and PML-RARA degradation in a caspase-dependent manner by inhibiting the β-catenin signalling pathway. This study proposes a novel treatment strategy for patients with APL, particularly those with ATRA-resistant APL. Topics: Amphibian Venoms; Apoptosis; bcl-2-Associated X Protein; beta Catenin; Bufanolides; Caspase 3; Caspases; Cyclin D1; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Receptors, Retinoic Acid | 2022 |